Delivery Order SPE2DB24D6044-SPE2DB25FLHTM

Award Date 3/26/25
Potential Completion Date 3/27/25
Potential Value $3.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,324.50, is for the delivery of Ropivacaine 0.2% 400 mg/200 ml medication. The contract has an ultimate completion date of January 9, 2024 and is a firm fixed-price Delivery Order. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,781.85, is a Delivery Order for the supply of Ropivacaine 0.2% 400 mg/200 ml medical products. The award is not associated with any set-aside program and has an ultimate completion date of May 24, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,074.33 firm fixed-price contract is for the supply of 4567794869 - Ropivacaine 0.2% 200 mg/100 ml, 100 ml, with a completion date of April 4, 2025. This contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $4,861.66 firm fixed-price delivery order is for the supply of 400 mg/200 mL ropivacaine 0.2% injectables. The contract has a period of performance through December 3, 2024 and was awarded on December 2, 2020. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,526.20 firm fixed-price delivery order is for the supply of 200 mg/100 mL vials of the medication ropivacaine 0.2%. The contract has an ultimate completion date of October 24, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of 400 mg/200 mL bottles of the pharmaceutical drug Ropivacaine 0.2%. The contract is a Delivery Order valued at $2,734.75 with a firm fixed price, and has an ultimate completion date of March 12, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $1,730.17, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office Division. The contract is for the delivery of 4565221300 - Ropivacaine 0.2% 200 mg/100 ml, a pharmaceutical product, to support military treatment facilities and programs. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and does not have a set-aside designation. Amerisourcebergen, as a major...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of Ropivacaine 0.2% 400 mg/200 ml medication. The contract has a ceiling value of $1,741.02 and a performance period that runs through April 2, 2025. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an award value of $7,820.39 and is for the delivery of ropivacaine 0.2% 400 mg/200 ml, a pain management medication. The contract has an ultimate completion date of September 25, 2023 and is a Firm Fixed Price Delivery Order. Based on the information provided, this contract award does not have a set-aside...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a for-profit pharmaceutical distributor, for the delivery of 4564014130 - Ropivacaine 0.2% 400 mg/200 ml, a specialty brand name medication. The award, valued at $7,621.52, is a firm fixed price delivery order with a completion date of March 20, 2024. AmerisourceBergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA valued at up to $999,999,999.00...
  • SPE2DB24D6044
    Indefinite Delivery Contract
  • SPE2DB24D6044-SPE2DB25FLHTM
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,571.90, is for the delivery of 400 mg/200 mL Ropivacaine 0.2% injection. This is a firm fixed-price delivery order contract with a completion date of March 27, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award did not have a set-aside designation, indicating open competition.

Generated 7/1/25, 8:54 AM